Tag: haemodialysis access

amplifi veith 2021

Amplifi vein dilation system demonstrates “encouraging” clinical results in haemodialysis access

Artio Medical has announced that full results from its first-in-human clinical study of the Amplifi vein dilation system were presented at the 2021 VEITHSymposium...
ellipsys five-year data

Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data

The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
wrapsody first study

“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...

Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
amplifi viva 2021

Results from first-in-human study of Amplifi vein dilation system presented at...

Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October...
amplifi vein dilation system

Artio Medical completes enrolment of first-in-human trial investigating Amplifi vein dilation...

Artio Medical announced today it has completed enrolment in its first-in-human study evaluating the Amplifi vein dilation system. In the study, five patients were treated...
trerotola misra tan av access dcbs drug coated balloons

More mixed results for DCBs in AV access maintenance as evidence...

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
covera

A thumbnail sketch of haemodialysis access: Past, present, and future in...

Bart Dolmatch gives an overview of the history of haemodialysis access in the USA, and balances the pros and cons of current access options....

Addressing the data deficit for drug-coated balloon use in dialysis access

The first 24-month data from the LUTONIX AV investigational device exemption trial were presented at the Charing Cross Symposium in April. These interim data...

From innovation to practice: The Ellipsys vascular access system

This is an exciting time for vascular access. Minimally invasive anastomosis devices have been developed and are being utilised in the creation of percutaneous...